Timothy A. Hacker, PhD

Position title: Director, Cardiovascular Physiology Core Facility, Medicine

Email: th2@medicine.wisc.edu

Website: morcore.cvrc.wisc.edu

Phone: 608-263-1539

Organ System/Disease Focus:
Aligned Research Focus:
Animal models of disease
Timothy Hacker headshot


More Information:
Research Description:

Dr. Hacker is the Director of Cardiovascular Physiology Core Facility, which is designed to create and analyze animal models of disease for basic science and pre-clinical testing of cell and other therapeutics. This service is provided to University of Wisconsin-Madison and outside researchers, including industry scientists on a fee-for-service basis. While the central focus of the facility is cardiovascular research, the techniques employed are useful to a number of investigators in other fields. Currently, the facility is conducting studies focusing on cell delivery devices and targeting, heart failure, arrhythmias and other cardiovascular diseases and various gene, drug and cell therapies to alter the course of the disease. We have fully equipped small and large animal operating theaters, echocardiography for large and small animals and many different devices for both acute and chronic physiologic monitoring.

Selected References:
  • Schmuck EG, Koch JM, Hacker TA, Hatt CR, Tomkowiak MT, Vigen KK, Hendren N, Leitzke C, Zhao YQ, Li Z, Centanni JM, Hei DJ, Schwahn D, Kim J, Hematti P, Raval AN. Intravenous Followed by X-ray Fused with MRI-Guided Transendocardial Mesenchymal Stem Cell Injection Improves Contractility Reserve in a Swine Model of Myocardial Infarction. J Cardiovasc Transl Res. 2015 Oct;8(7):438-48. doi: 10.1007/s12265-015-9654-0. Epub 2015 Sep 15. PubMed PMID: 26374144.
  • Lalit PA, Salick MR, Nelson DO, Squirrell JM, Shafer CM, Patel NG, Saeed I, Schmuck EG, Markandeya YS, Wong R, Lea MR, Eliceiri KW, Hacker TA, Crone WC, Kyba M, Garry DJ, Stewart R, Thomson JA, Downs KM, Lyons GE, Kamp TJ. Lineage Reprogramming of Fibroblasts into Proliferative Induced Cardiac Progenitor Cells by Defined Factors. Cell Stem Cell. 2016 Mar 3;18(3):354-67. doi: 10.1016/j.stem.2015.12.001. Epub 2016 Feb 11. PubMed PMID: 26877223; PubMed Central PMCID: PMC4779406.
  • Koch JM, D’Souza SS, Schwahn DJ, Dixon I, Hacker TA. Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy. 2016 Feb;18(2):219-28. doi: 10.1016/j.jcyt.2015.10.013. Epub 2015 Dec 28. PubMed PMID: 26740280.
  • Schmuck EG, Koch JM, Centanni JM, Hacker TA, Braun RK, Eldridge M, Hei DJ, Hematti P, Raval AN., Biodistribution and Clearance of Human Mesenchymal Stem Cells by Quantitative Three-Dimensional Cryo-Imaging After Intravenous Infusion in a Rat Lung Injury Model. Stem Cells Transl Med. 2016 Dec;5(12):1668-1675. Epub 2016 Jul 26. PMID: 27460855
  • Braun RK, Koch JM, Hacker TA, Pegelow D, Kim J, Raval AN, Schmuck EG, Schwahn DJ, Hei DJ, Centanni JM, Eldridge M, Hematti P., Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion. Cytotherapy. 2016 Apr;18(4):536-45. doi: 10.1016/j.jcyt.2016.01.010. PMID: 26971682